Thrombopoietin (TPO)
Overview
Thrombopoietin is a 332-amino acid endogenous glycoprotein hormone and the primary physiologic regulator of megakaryopoiesis and platelet production. It binds to the c-Mpl receptor on megakaryocyte progenitors and mature megakaryocytes, stimulating their proliferation, differentiation, and platelet release. Recombinant TPO and pegylated recombinant megakaryocyte growth and development factor (PEG-rHuMGDF) were developed but abandoned after clinical trials revealed antibody-mediated thrombocytopenia.
Key Research Findings
Early clinical trials of recombinant TPO in the 1990s showed efficacy in chemotherapy-induced thrombocytopenia, but development was halted after healthy volunteers and cancer patients developed neutralizing antibodies that cross-reacted with endogenous TPO, causing severe thrombocytopenia. This experience led to development of non-immunogenic TPO receptor agonists such as romiplostim and eltrombopag that do not share sequence homology with native TPO.
Subcutaneous injection, Intravenous
Investigational
Interested in Thrombopoietin (TPO)?
Find a verified provider experienced with Thrombopoietin (TPO) protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Thrombopoietin (TPO) ProviderRelated Peptides
Bivalirudin (Angiomax)
FDA ApprovedA synthetic 20-amino acid peptide that acts as a direct thrombin inhibitor by binding both the catalytic active site and anion-binding exosite 1 of thrombin. Bivalirudin inhibits both free and clot-bound thrombin, providing more predictable anticoagulation than heparin without requiring antithrombin III as a cofactor. It is enzymatically cleaved by thrombin itself, producing a self-limiting anticoagulant effect with a 25-minute half-life.
Romiplostim (Nplate)
FDA ApprovedA thrombopoietin (TPO) receptor agonist consisting of a peptide sequence that binds the TPO receptor (c-Mpl) fused to an IgG1 Fc domain (peptibody). Romiplostim activates JAK2/STAT5 signaling in megakaryocyte progenitors, promoting megakaryocyte proliferation, differentiation, and platelet production. It has no sequence homology to endogenous TPO, minimizing the risk of cross-reactive antibody formation.
Pegcetacoplan (Empaveli)
FDA ApprovedA pegylated cyclic peptide that inhibits complement component C3, the central node of all three complement activation pathways (classical, lectin, and alternative). By binding C3 and preventing its cleavage into C3a and C3b, pegcetacoplan blocks both intravascular hemolysis (mediated by membrane attack complex) and extravascular hemolysis (mediated by C3b opsonization and phagocytosis). This dual mechanism addresses the limitation of C5 inhibitors that only prevent intravascular hemolysis.
Peginesatide (Omontys)
FDA ApprovedPeginesatide is a synthetic pegylated peptide-based erythropoiesis-stimulating agent (ESA) consisting of two 21-amino acid chains linked to polyethylene glycol. Unlike recombinant erythropoietin, it contains no erythropoietin sequence homology yet activates the erythropoietin receptor to stimulate red blood cell production. The pegylation confers a prolonged half-life, enabling once-monthly dosing in dialysis-dependent chronic kidney disease.